CAR-T细胞疗法市场－全球产业规模、份额、趋势、机会和预测，按产品类型、肿瘤类型、适应症、治疗类型、标靶抗原、最终用户、地区和竞争格局划分，2020-2030年预测

2024年全球CAR-T细胞疗法市场规模为38.7亿美元，预计2030年将以22.77%的复合年增长率成长至132.5亿美元。嵌合抗原受体（CAR）-T细胞疗法是一种先进的免疫疗法，其原理是透过基因工程改造患者自身的T细胞，使其表达靶向癌细胞表面特定抗原的受体。此市场的成长主要受以下因素驱动：全球血液系统恶性肿瘤发生率的上升、CAR-T细胞疗法在復发或难治性患者群体中展现出的高效性和持久疗效，以及旨在拓展治疗适应症和提高治疗可及性的研发投入。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球CAR-T细胞疗法市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依产品类型（Yescarta、Kymriah、Tecartus、Breyanzi、Abecma）
  • 依肿瘤类型（血液系统恶性肿瘤、实体肿瘤）
  • 依适应症（瀰漫性大B细胞淋巴瘤（DLBCL）、急性淋巴母细胞白血病（ALL）、滤泡性淋巴瘤（FL）、套细胞淋巴瘤（MCL）、其他）
  • 目标抗原（D19、BCMA（B细胞成熟抗原）、其他）
  • 按最终使用者（医院、专科诊所、门诊手术中心、其他）
  • 依治疗类型（单一疗法、合併疗法）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美CAR-T细胞疗法市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲CAR-T细胞疗法市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区CAR-T细胞疗法市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲CAR-T细胞疗法市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美CAR-T细胞疗法市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球CAR-T细胞疗法市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Gilead Sciences, Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Cellectis SA
• Amgen Inc.
• Pfizer Inc
• Merck KgaA
• Intellia Therapeutics, Inc.
• Johnson & Johnson

第十六章：策略建议

第17章调查会社について・免责事项

The Global CAR-T Cell Therapy Market, valued at USD 3.87 Billion in 2024, is projected to experience a CAGR of 22.77% to reach USD 13.25 Billion by 2030. Chimeric Antigen Receptor (CAR)-T cell therapy represents an advanced form of immunotherapy where a patient's T cells are genetically engineered to express a receptor targeting specific antigens on cancer cells. The market's expansion is primarily driven by the increasing global incidence of hematological malignancies, the demonstrated high efficacy and durable responses observed in relapsed or refractory patient populations, and substantial investment in research and development aimed at broadening therapeutic indications and enhancing treatment accessibility.

Key Market Drivers

The global CAR-T cell therapy market is significantly influenced by the demonstrated high efficacy of these treatments in hematologic malignancies and the expanding regulatory approvals for new indications. The proven ability of CAR-T therapies to induce deep and durable responses in patient populations with limited alternative options provides a compelling clinical rationale for their adoption and growth. For instance, according to Bristol Myers Squibb and 2seventy bio, in February 2023, the Phase 3 KarMMa-3 study demonstrated that Abecma achieved a 71% overall response rate in patients with relapsed or refractory multiple myeloma. This robust clinical performance underscores the transformative potential of CAR-T cells, driving demand and investment in this therapeutic area.

Key Market Challenges

The substantial cost associated with personalized CAR-T cell treatments represents a significant barrier to the global market's expansion. These high costs severely limit broader patient access and place considerable strain on healthcare systems, directly impeding the widespread adoption of these therapies. The financial burden creates substantial hurdles for both patients and healthcare providers, restricting the volume of treatments administered.

Key Market Trends

Expansion into Solid Tumor Indications represents a crucial diversification beyond the initial successes in hematologic malignancies, opening significant new market segments. The inherent complexities of solid tumors, such as their immunosuppressive microenvironments and heterogeneous antigen expression, have historically presented considerable challenges for CAR-T cell efficacy. However, ongoing research and technological innovations are addressing these barriers through enhanced CAR designs, localized delivery methods, and combinatorial approaches. Progress in this area is evidenced by the growing number of clinical investigations, with solid tumors constituting 24.6% of CAR-T clinical trials as of May 2025, according to insights from Frontiers. This expansion into a broader range of cancer types is pivotal for realizing the full therapeutic and commercial potential of CAR-T cell therapy, moving it towards a more widespread application in oncology.

Key Market Players

• Gilead Sciences, Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Cellectis SA
• Amgen Inc.
• Pfizer Inc
• Merck KgaA
• Intellia Therapeutics, Inc.
• Johnson & Johnson

Report Scope:

In this report, the Global CAR-T Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

CAR-T Cell Therapy Market, By Product Type:

• Yescarta
• Kymriah
• Tecartus
• Breyanzi
• Abecma

CAR-T Cell Therapy Market, By Tumor Type:

• Hematological Malignancies
• Solid Tumors

CAR-T Cell Therapy Market, By Indication:

• Diffused Large B-Cell Lymphoma (DLBCL)
• Acute Lymphoblastic Leukemia (ALL)
• Follicular Lymphoma (FL)
• Mantle Cell Lymphoma (MCL)
• Others

CAR-T Cell Therapy Market, By Targeted Antigen:

• D 19
• BCMA (B-Cell Maturation Antigen)
• Others

CAR-T Cell Therapy Market, By End User:

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

CAR-T Cell Therapy Market, By Treatment Type:

• Single Treatment
• Combination Treatment

CAR-T Cell Therapy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global CAR-T Cell Therapy Market.

Available Customizations:

Global CAR-T Cell Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global CAR-T Cell Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Yescarta, Kymriah, Tecartus, Breyanzi, Abecma)
  • 5.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
  • 5.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
  • 5.2.4. By Targeted Antigen (D 19, BCMA (B-Cell Maturation Antigen), Others)
  • 5.2.5. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.6. By Treatment Type (Single Treatment, Combination Treatment)
  • 5.2.7. By Region
  • 5.2.8. By Company (2024)
• 5.3. Market Map

6. North America CAR-T Cell Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Tumor Type
  • 6.2.3. By Indication
  • 6.2.4. By Targeted Antigen
  • 6.2.5. By End User
  • 6.2.6. By Treatment Type
  • 6.2.7. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States CAR-T Cell Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Tumor Type
      • 6.3.1.2.3. By Indication
      • 6.3.1.2.4. By Targeted Antigen
      • 6.3.1.2.5. By End User
      • 6.3.1.2.6. By Treatment Type
  • 6.3.2. Canada CAR-T Cell Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Tumor Type
      • 6.3.2.2.3. By Indication
      • 6.3.2.2.4. By Targeted Antigen
      • 6.3.2.2.5. By End User
      • 6.3.2.2.6. By Treatment Type
  • 6.3.3. Mexico CAR-T Cell Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Tumor Type
      • 6.3.3.2.3. By Indication
      • 6.3.3.2.4. By Targeted Antigen
      • 6.3.3.2.5. By End User
      • 6.3.3.2.6. By Treatment Type

7. Europe CAR-T Cell Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Tumor Type
  • 7.2.3. By Indication
  • 7.2.4. By Targeted Antigen
  • 7.2.5. By End User
  • 7.2.6. By Treatment Type
  • 7.2.7. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany CAR-T Cell Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Tumor Type
      • 7.3.1.2.3. By Indication
      • 7.3.1.2.4. By Targeted Antigen
      • 7.3.1.2.5. By End User
      • 7.3.1.2.6. By Treatment Type
  • 7.3.2. France CAR-T Cell Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Tumor Type
      • 7.3.2.2.3. By Indication
      • 7.3.2.2.4. By Targeted Antigen
      • 7.3.2.2.5. By End User
      • 7.3.2.2.6. By Treatment Type
  • 7.3.3. United Kingdom CAR-T Cell Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Tumor Type
      • 7.3.3.2.3. By Indication
      • 7.3.3.2.4. By Targeted Antigen
      • 7.3.3.2.5. By End User
      • 7.3.3.2.6. By Treatment Type
  • 7.3.4. Italy CAR-T Cell Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Tumor Type
      • 7.3.4.2.3. By Indication
      • 7.3.4.2.4. By Targeted Antigen
      • 7.3.4.2.5. By End User
      • 7.3.4.2.6. By Treatment Type
  • 7.3.5. Spain CAR-T Cell Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Tumor Type
      • 7.3.5.2.3. By Indication
      • 7.3.5.2.4. By Targeted Antigen
      • 7.3.5.2.5. By End User
      • 7.3.5.2.6. By Treatment Type

8. Asia Pacific CAR-T Cell Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Tumor Type
  • 8.2.3. By Indication
  • 8.2.4. By Targeted Antigen
  • 8.2.5. By End User
  • 8.2.6. By Treatment Type
  • 8.2.7. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China CAR-T Cell Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Tumor Type
      • 8.3.1.2.3. By Indication
      • 8.3.1.2.4. By Targeted Antigen
      • 8.3.1.2.5. By End User
      • 8.3.1.2.6. By Treatment Type
  • 8.3.2. India CAR-T Cell Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Tumor Type
      • 8.3.2.2.3. By Indication
      • 8.3.2.2.4. By Targeted Antigen
      • 8.3.2.2.5. By End User
      • 8.3.2.2.6. By Treatment Type
  • 8.3.3. Japan CAR-T Cell Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Tumor Type
      • 8.3.3.2.3. By Indication
      • 8.3.3.2.4. By Targeted Antigen
      • 8.3.3.2.5. By End User
      • 8.3.3.2.6. By Treatment Type
  • 8.3.4. South Korea CAR-T Cell Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Tumor Type
      • 8.3.4.2.3. By Indication
      • 8.3.4.2.4. By Targeted Antigen
      • 8.3.4.2.5. By End User
      • 8.3.4.2.6. By Treatment Type
  • 8.3.5. Australia CAR-T Cell Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Tumor Type
      • 8.3.5.2.3. By Indication
      • 8.3.5.2.4. By Targeted Antigen
      • 8.3.5.2.5. By End User
      • 8.3.5.2.6. By Treatment Type

9. Middle East & Africa CAR-T Cell Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Tumor Type
  • 9.2.3. By Indication
  • 9.2.4. By Targeted Antigen
  • 9.2.5. By End User
  • 9.2.6. By Treatment Type
  • 9.2.7. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia CAR-T Cell Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Tumor Type
      • 9.3.1.2.3. By Indication
      • 9.3.1.2.4. By Targeted Antigen
      • 9.3.1.2.5. By End User
      • 9.3.1.2.6. By Treatment Type
  • 9.3.2. UAE CAR-T Cell Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Tumor Type
      • 9.3.2.2.3. By Indication
      • 9.3.2.2.4. By Targeted Antigen
      • 9.3.2.2.5. By End User
      • 9.3.2.2.6. By Treatment Type
  • 9.3.3. South Africa CAR-T Cell Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Tumor Type
      • 9.3.3.2.3. By Indication
      • 9.3.3.2.4. By Targeted Antigen
      • 9.3.3.2.5. By End User
      • 9.3.3.2.6. By Treatment Type

10. South America CAR-T Cell Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Tumor Type
  • 10.2.3. By Indication
  • 10.2.4. By Targeted Antigen
  • 10.2.5. By End User
  • 10.2.6. By Treatment Type
  • 10.2.7. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil CAR-T Cell Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Tumor Type
      • 10.3.1.2.3. By Indication
      • 10.3.1.2.4. By Targeted Antigen
      • 10.3.1.2.5. By End User
      • 10.3.1.2.6. By Treatment Type
  • 10.3.2. Colombia CAR-T Cell Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Tumor Type
      • 10.3.2.2.3. By Indication
      • 10.3.2.2.4. By Targeted Antigen
      • 10.3.2.2.5. By End User
      • 10.3.2.2.6. By Treatment Type
  • 10.3.3. Argentina CAR-T Cell Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Tumor Type
      • 10.3.3.2.3. By Indication
      • 10.3.3.2.4. By Targeted Antigen
      • 10.3.3.2.5. By End User
      • 10.3.3.2.6. By Treatment Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global CAR-T Cell Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Gilead Sciences, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Bristol-Myers Squibb Company
• 15.4. AbbVie Inc.
• 15.5. Cellectis SA
• 15.6. Amgen Inc.
• 15.7. Pfizer Inc
• 15.8. Merck KgaA
• 15.9. Intellia Therapeutics, Inc.
• 15.10. Johnson & Johnson

16. Strategic Recommendations

17. About Us & Disclaimer